My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

71.05 +1.08 (+1.54%)
Streaming Delayed Price Updated: 12:57 PM EDT, Oct 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 847,887
Open 70.16
Bid (Size) 71.02 (5)
Ask (Size) 71.10 (6)
Prev. Close 69.97
Today's Range 69.84 - 71.42
52wk Range 23.95 - 71.87
Shares Outstanding 141,797,854
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook
Carlsbad, CA – October 8, 2025 – Ionis Pharmaceuticals (NASDAQ:IONS) is currently witnessing a remarkable surge in its stock value, nearing a six-year high. This impressive ascent is largely driven by... 
Via MarketMinute
Why Ionis Stock, Approaching A Six-Year High, Just Snagged A Price-Target Hike
The company is working toward a potential $5 billion sales peak for its partnered and unpartnered programs. 
Via Investor's Business Daily

Performance

YTD
+104.8%
+104.8%
1 Month
+12.5%
+12.5%
3 Month
+67.0%
+67.0%
6 Month
+147.7%
+147.7%
1 Year
+83.9%
+83.9%

More News

Read More
This Penumbra Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday
Via Benzinga
Ionis Pharma Stock Rises After Multiple Price Target Hikes On Heels Of Positive Study Results In Alexander Disease
Via Stocktwits
Ionis showcases transformational medicines and industry-leading pipeline at Innovation Day
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen
From Biogen Inc.
Via GlobeNewswire
What Analysts Are Saying About Ionis Pharmaceuticals Stock
Via Benzinga
Ionis Pharmaceuticals Reveals 'Unprecedented Results' From Rare Neurological Disease Trial
Via Benzinga
Ionis announces positive topline results from pivotal study of zilganersen in Alexander disease
From Ionis Pharmaceuticals, Inc.
Via Business Wire
TRYNGOLZA® (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS)
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates
From Biogen Inc.
Via GlobeNewswire
Ionis expands Surf Away+ event, marking 10 years of creating unique adaptive experiences for people with neurological diseases
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Ionis Pharmaceuticals To Expedite Development Of Rare Neurological Disease Candidate With FDA Breakthrough Status
Via Benzinga
Ionis receives U.S. FDA Breakthrough Therapy designation for ION582 in Angelman syndrome
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Ionis to host investors and analysts for Innovation Day 2025
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Ionis to present at upcoming investor conferences
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Here are the top movers in Tuesday's session.
Via Chartmill
IONS Stock Soars 34% To Hit February 2021 Highs After Medicine Shows Positive Effect On Elevated Triglyceride Levels In Late-Stage Studies
Via Stocktwits
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Ionis Pharma's Investigational Drug Shows Promise For Triglyceride And Pancreatitis Reduction
Via Benzinga
There are notable gap-ups and gap-downs in today's session.
Via Chartmill
Ionis Pharma Hits The 'Bull Case,' 'Blue Sky' In Lowering Triglycerides. Shares Launch.
Via Investor's Business Daily
Olezarsen significantly reduces triglycerides and acute pancreatitis events in landmark pivotal studies for people with severe hypertriglyceridemia (sHTG)
From Ionis Pharmaceuticals, Inc.
Via Business Wire
IONIS PHARMACEUTICALS INC (NASDAQ:IONS) Presents a High-Probability Technical Breakout Setup
Via Chartmill

Frequently Asked Questions

Is Ionis Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Ionis Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Ionis Pharmaceuticals, Inc. - Common Stock trade on?
Ionis Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Ionis Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Ionis Pharmaceuticals, Inc. - Common Stock is IONS on the Nasdaq Stock Market
What is the current price of Ionis Pharmaceuticals, Inc. - Common Stock?
The current price of Ionis Pharmaceuticals, Inc. - Common Stock is 71.05
When was Ionis Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Ionis Pharmaceuticals, Inc. - Common Stock was at 10/13/25 12:57 PM ET
What is the market capitalization of Ionis Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Ionis Pharmaceuticals, Inc. - Common Stock is 10.07B
How many shares of Ionis Pharmaceuticals, Inc. - Common Stock are outstanding?
Ionis Pharmaceuticals, Inc. - Common Stock has 10B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.